Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clinical validity and utility of complex biomarkers ha...
Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2018-05-01
|
Series: | Journal for ImmunoTherapy of Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40425-018-0344-8 |
id |
doaj-956c5246c411433fb1a686b13fb6565c |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Carl Morrison Sarabjot Pabla Jeffrey M. Conroy Mary K. Nesline Sean T. Glenn Devin Dressman Antonios Papanicolau-Sengos Blake Burgher Jonathan Andreas Vincent Giamo Moachun Qin Yirong Wang Felicia L. Lenzo Angela Omilian Wiam Bshara Matthew Zibelman Pooja Ghatalia Konstantin Dragnev Keisuke Shirai Katherine G. Madden Laura J. Tafe Neel Shah Deepa Kasuganti Luis de la Cruz-Merino Isabel Araujo Yvonne Saenger Margaret Bogardus Miguel Villalona-Calero Zuanel Diaz Roger Day Marcia Eisenberg Steven M. Anderson Igor Puzanov Lorenzo Galluzzi Mark Gardner Marc S. Ernstoff |
spellingShingle |
Carl Morrison Sarabjot Pabla Jeffrey M. Conroy Mary K. Nesline Sean T. Glenn Devin Dressman Antonios Papanicolau-Sengos Blake Burgher Jonathan Andreas Vincent Giamo Moachun Qin Yirong Wang Felicia L. Lenzo Angela Omilian Wiam Bshara Matthew Zibelman Pooja Ghatalia Konstantin Dragnev Keisuke Shirai Katherine G. Madden Laura J. Tafe Neel Shah Deepa Kasuganti Luis de la Cruz-Merino Isabel Araujo Yvonne Saenger Margaret Bogardus Miguel Villalona-Calero Zuanel Diaz Roger Day Marcia Eisenberg Steven M. Anderson Igor Puzanov Lorenzo Galluzzi Mark Gardner Marc S. Ernstoff Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden Journal for ImmunoTherapy of Cancer Pembrolizumab Nivolumab Ipilimumab Algorithmic analysis Inflamed Borderline |
author_facet |
Carl Morrison Sarabjot Pabla Jeffrey M. Conroy Mary K. Nesline Sean T. Glenn Devin Dressman Antonios Papanicolau-Sengos Blake Burgher Jonathan Andreas Vincent Giamo Moachun Qin Yirong Wang Felicia L. Lenzo Angela Omilian Wiam Bshara Matthew Zibelman Pooja Ghatalia Konstantin Dragnev Keisuke Shirai Katherine G. Madden Laura J. Tafe Neel Shah Deepa Kasuganti Luis de la Cruz-Merino Isabel Araujo Yvonne Saenger Margaret Bogardus Miguel Villalona-Calero Zuanel Diaz Roger Day Marcia Eisenberg Steven M. Anderson Igor Puzanov Lorenzo Galluzzi Mark Gardner Marc S. Ernstoff |
author_sort |
Carl Morrison |
title |
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden |
title_short |
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden |
title_full |
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden |
title_fullStr |
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden |
title_full_unstemmed |
Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden |
title_sort |
predicting response to checkpoint inhibitors in melanoma beyond pd-l1 and mutational burden |
publisher |
BMJ Publishing Group |
series |
Journal for ImmunoTherapy of Cancer |
issn |
2051-1426 |
publishDate |
2018-05-01 |
description |
Abstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clinical validity and utility of complex biomarkers have not been studied in melanoma. Methods Cutaneous metastatic melanoma patients at eight institutions were evaluated for PD-L1 expression, CD8+ T-cell infiltration pattern, mutational burden, and 394 immune transcript expression. PD-L1 IHC and mutational burden were assessed for association with overall survival (OS) in 94 patients treated prior to ICI approval by the FDA (historical-controls), and in 137 patients treated with ICIs. Unsupervised analysis revealed distinct immune-clusters with separate response rates. This comprehensive immune profiling data were then integrated to generate a continuous Response Score (RS) based upon response criteria (RECIST v.1.1). RS was developed using a single institution training cohort (n = 48) and subsequently tested in a separate eight institution validation cohort (n = 29) to mimic a real-world clinical scenario. Results PD-L1 positivity ≥1% correlated with response and OS in ICI-treated patients, but demonstrated limited predictive performance. High mutational burden was associated with response in ICI-treated patients, but not with OS. Comprehensive immune profiling using RS demonstrated higher sensitivity (72.2%) compared to PD-L1 IHC (34.25%) and tumor mutational burden (32.5%), but with similar specificity. Conclusions In this study, the response score derived from comprehensive immune profiling in a limited melanoma cohort showed improved predictive performance as compared to PD-L1 IHC and tumor mutational burden. |
topic |
Pembrolizumab Nivolumab Ipilimumab Algorithmic analysis Inflamed Borderline |
url |
http://link.springer.com/article/10.1186/s40425-018-0344-8 |
work_keys_str_mv |
AT carlmorrison predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT sarabjotpabla predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT jeffreymconroy predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT maryknesline predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT seantglenn predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT devindressman predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT antoniospapanicolausengos predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT blakeburgher predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT jonathanandreas predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT vincentgiamo predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT moachunqin predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT yirongwang predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT feliciallenzo predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT angelaomilian predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT wiambshara predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT matthewzibelman predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT poojaghatalia predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT konstantindragnev predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT keisukeshirai predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT katherinegmadden predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT laurajtafe predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT neelshah predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT deepakasuganti predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT luisdelacruzmerino predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT isabelaraujo predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT yvonnesaenger predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT margaretbogardus predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT miguelvillalonacalero predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT zuaneldiaz predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT rogerday predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT marciaeisenberg predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT stevenmanderson predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT igorpuzanov predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT lorenzogalluzzi predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT markgardner predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden AT marcsernstoff predictingresponsetocheckpointinhibitorsinmelanomabeyondpdl1andmutationalburden |
_version_ |
1724869273547964416 |
spelling |
doaj-956c5246c411433fb1a686b13fb6565c2020-11-25T02:20:52ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262018-05-016111210.1186/s40425-018-0344-8Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burdenCarl Morrison0Sarabjot Pabla1Jeffrey M. Conroy2Mary K. Nesline3Sean T. Glenn4Devin Dressman5Antonios Papanicolau-Sengos6Blake Burgher7Jonathan Andreas8Vincent Giamo9Moachun Qin10Yirong Wang11Felicia L. Lenzo12Angela Omilian13Wiam Bshara14Matthew Zibelman15Pooja Ghatalia16Konstantin Dragnev17Keisuke Shirai18Katherine G. Madden19Laura J. Tafe20Neel Shah21Deepa Kasuganti22Luis de la Cruz-Merino23Isabel Araujo24Yvonne Saenger25Margaret Bogardus26Miguel Villalona-Calero27Zuanel Diaz28Roger Day29Marcia Eisenberg30Steven M. Anderson31Igor Puzanov32Lorenzo Galluzzi33Mark Gardner34Marc S. Ernstoff35Center for Personalized Medicine, Roswell Park Comprehensive Cancer CenterOmniSeq Inc.Center for Personalized Medicine, Roswell Park Comprehensive Cancer CenterOmniSeq Inc.Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer CenterOmniSeq Inc.OmniSeq Inc.OmniSeq Inc.OmniSeq Inc.OmniSeq Inc.OmniSeq Inc.OmniSeq Inc.OmniSeq Inc.Department of Pathology, Roswell Park Comprehensive Cancer CenterDepartment of Pathology, Roswell Park Comprehensive Cancer CenterDepartment of Hematology/Oncology, Fox Chase Cancer CenterDepartment of Hematology/Oncology, Fox Chase Cancer CenterDepartment of Hematology and Oncology, Dartmouth HitchcockDepartment of Hematology and Oncology, Dartmouth HitchcockDepartment of Hematology and Oncology, Dartmouth HitchcockDepartment of Hematology and Oncology, Dartmouth HitchcockDepartment of Pathology, Community HospitalDepartment of Pathology, Community HospitalDepartment of Clinical Oncology Development, Hospital Universitario Virgen MacarenaDepartment of Clinical Oncology Development, Hospital Universitario Virgen MacarenaDepartment of Medicine, Columbia UniversityDepartment of Medicine, Columbia UniversityMiami Cancer Institute, Baptist Health South FloridaMiami Cancer Institute, Baptist Health South FloridaDepartment of Biomedical Informatics and Biostatistics, University of PittsburghLaboratory Corporation of America HoldingsLaboratory Corporation of America HoldingsDepartment of Medicine, Roswell Park Comprehensive Cancer CenterDepartment of Radiation Oncology, Weill Cornell Medical CollegeOmniSeq Inc.Department of Medicine, Roswell Park Comprehensive Cancer CenterAbstract Background Immune checkpoint inhibitors (ICIs) have changed the clinical management of melanoma. However, not all patients respond, and current biomarkers including PD-L1 and mutational burden show incomplete predictive performance. The clinical validity and utility of complex biomarkers have not been studied in melanoma. Methods Cutaneous metastatic melanoma patients at eight institutions were evaluated for PD-L1 expression, CD8+ T-cell infiltration pattern, mutational burden, and 394 immune transcript expression. PD-L1 IHC and mutational burden were assessed for association with overall survival (OS) in 94 patients treated prior to ICI approval by the FDA (historical-controls), and in 137 patients treated with ICIs. Unsupervised analysis revealed distinct immune-clusters with separate response rates. This comprehensive immune profiling data were then integrated to generate a continuous Response Score (RS) based upon response criteria (RECIST v.1.1). RS was developed using a single institution training cohort (n = 48) and subsequently tested in a separate eight institution validation cohort (n = 29) to mimic a real-world clinical scenario. Results PD-L1 positivity ≥1% correlated with response and OS in ICI-treated patients, but demonstrated limited predictive performance. High mutational burden was associated with response in ICI-treated patients, but not with OS. Comprehensive immune profiling using RS demonstrated higher sensitivity (72.2%) compared to PD-L1 IHC (34.25%) and tumor mutational burden (32.5%), but with similar specificity. Conclusions In this study, the response score derived from comprehensive immune profiling in a limited melanoma cohort showed improved predictive performance as compared to PD-L1 IHC and tumor mutational burden.http://link.springer.com/article/10.1186/s40425-018-0344-8PembrolizumabNivolumabIpilimumabAlgorithmic analysisInflamedBorderline |